Endo ERN
Find an expert
Endo ERN
Search
  • Rare Endocrine Conditions

    Endocrine Conditions

    Endo-ERN is focused on 8 main thematic groups (MTGs) which cover rare and/or complex endocrine conditions

    Go to overview

    Categories

    • MTG1Adrenal
    • MTG2Disorders of Calcium & Phosphate Homeostasis
    • MTG3Genetic Disorders of Glucose & Insulin Homeostasis
    • MTG4Genetic Endocrine Tumour Syndromes
    • MTG5Growth & Genetic Obesity Syndromes
    • MTG6Hypothalamic and Pituitary Conditions
    • MTG7Sex Development & Maturation
    • MTG8Thyroid
  • About Us

    About Us

    Endo-ERN is a network of 100+ Reference Centres (RCs) in 27 EU member states+Norway that offers access to clinical experts for patients with rare endocrine conditions.  

    Go to overview

    Who we are

    • About Endo-ERN
    • What we do
    • Reference centres
    • Work packages
    • Project team

    Information

    • Events
    • FAQ
    • Newsletter
    • Contact
    • ERNs
  • For Professionals

    For Professionals

    Endo-ERN is the network for rare endocrine conditions providing healthcare professionals with access to a variety of resources to support patient care.  

    Our Network

    • About Endo-ERN
    • Find a Reference Centre

    Research

    • Registries
    • Publications
    • Clinical Trials

    Support Tools

    • Virtual Consultations
    • Guidelines
    • COVID-19

    Training & Education

    • Webinars
    • Exchange Programme
  • For Members

    For Members

    If you work at a member institution this page will help with your Endo-ERN contributions.  

    Go to overview

    Quick Links

    • Cite Endo-ERN
    • CPMS 2.0
    • GA2026
    • The Journal

    Evaluation

    • Continuous Monitoring Exercise
    • 5-year evaluation
    • HCP Performance System

    Network Participation

    • Event Endorsement
    • Member Survey
    • Webinar Planning
    • MTG Representatives

    Membership Management

    • Update Member Contacts
    • Request Disease Area Expansion
    • Termination Policy
  • For Patients

    For Patients

    Access to rare disease expertise without the need to travel is a core ERN objective.  Our ePAGs contribute to all Endo-ERN activities.  

    Go to overview

    Patient information

    • What are European Reference Networks?
    • Cross-border healthcare
    • Rare endocrine conditions
    • Patient materials

    ePAG information

    • European Patient Advocacy Groups
    • Patient representatives
    • How to become an Endo-ERN ePAG
  • Search
  • Rare Endocrine Conditions
  • About Us
  • For Professionals
  • For Members
  • For Patients
  • Search
  • Rare Endocrine Conditions
  • About Us
  • For Professionals
  • For Members
  • For Patients
  • Search
Endo ERN
Find an expert
Search
/ Publications Overview / Publications Database

Endo-ERN Publications Database

RDD IssuesBack to Publications Overview

Filter list of publications

890 publication(s) found matching the search criteria

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma


Author(s): Kimpel O, Schindler P, Schmidt-Pennington L, Altieri B, Megerle F, Haak H, Pittaway J, Dischinger U, Quinkler M, Mai K, Kroiss M, Polat B, Fassnacht M
Affiliated Institution / ERN: University Hospital Würzburg ; Charité Universitätsmedizin Berlin ;
Condition / Disease: Adrenocortical carcinoma
Publication: British Journal of Cancer v128.4 p586-593 Year: 2023 ORPHAcode / other: ORPHA1501
DOI: 10.1038/s41416-022-02082-0 Keywords:
MTG1

Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection


Author(s): Altieri B, La Salvia A, Modica R, Marciello F, Mercier O, Filosso PL, de Latour BR, Giuffrida D, Campione S, Guggino G, Fadel E, Papotti M, Colao A, Scoazec J, Baudin E, Faggiano A
Affiliated Institution / ERN: AOU Federico II - Naples ;
Condition / Disease: neuroendocrine tumor of the lung
Publication: Journal of Personalized Medicine v13.2 p330 Year: 2023 ORPHAcode / other: ORPHA877; ORPHA100101
DOI: 10.3390/jpm13020330 Keywords: LCNEC,adjuvant therapy,age,lymph nodes,neuroendocrine tumor,prognosis,prognostic marker,pulmonary cancer,surgery,survival
MTG4

The Italian registry for patients with Prader–Willi syndrome


Author(s): Salvatore M, Torreri P, Grugni G, Rocchetti A, Maghnie M, Patti G, Crinò A, Elia M, Greco D, Romano C, Franzese A, Mozzillo E, Colao A, Pugliese G, Pagotto U, Lo Preiato V, Scarano E, Schiavariello C, Tornese G, Fintini D, Bocchini S, Osimani S, De Sanctis L, Sacco M, Rutigliano I, Delvecchio M, Faienza MF, Wasniewska M, Corica D, Stagi S, Guazzarotti L, Maffei P, Dassie F, Taruscio D
Affiliated Institution / ERN:
Condition / Disease: Prader-Willi syndrome
Publication: Orphanet Journal of Rare Diseases v18.1 Year: 2023 ORPHAcode / other: ORPHA739
DOI: 10.1186/s13023-023-02633-5 Keywords: Genetic diseases,Prader–Willi syndrome,Quality,Rare diseases,Registry
MTG5

The Italian registry for patients with Prader–Willi syndrome


Author(s): Salvatore M, Torreri P, Grugni G, Rocchetti A, Maghnie M, Patti G, Crinò A, Elia M, Greco D, Romano C, Franzese A, Mozzillo E, Colao A, Pugliese G, Pagotto U, Lo Preiato V, Scarano E, Schiavariello C, Tornese G, Fintini D, Bocchini S, Osimani S, De Sanctis L, Sacco M, Rutigliano I, Delvecchio M, Faienza MF, Wasniewska M, Corica D, Stagi S, Guazzarotti L, Maffei P, Dassie F, Taruscio D
Affiliated Institution / ERN: University Hospital of Padova ; AOU Federico II - Naples ; AOU polyclinic "G.Martino" of Messina ; IRCCS Istituto Giannina Gaslini, Genova ; Meyer Children’s Hospital Florence ; San Raffaele hospital - Milan ;
Condition / Disease: Prader-Willi syndrome
Publication: Orphanet Journal of Rare Diseases v18.1 Year: 2023 ORPHAcode / other: ORPHA739
DOI: 10.1186/s13023-023-02633-5 Keywords: Genetic diseases,Prader–Willi syndrome,Quality,Rare diseases,Registry
MTG5

Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies


Author(s): Coerts HI, de Keizer B, Marlowe RJ, Verburg FA
Affiliated Institution / ERN: University Medical Center Utrecht ;
Condition / Disease: Thyroid cancer
Publication: European Journal of Endocrinology v188.2 pR23-R35 Year: 2023 ORPHAcode / other: ORPHA146
DOI: 10.1093/ejendo/lvad006 Keywords: radioactive iodine,recombinant human TSH,thyroid hormone withdrawal
MTG8

Non-invasive follicular thyroid neoplasm with papillary-like nuclear feature: clinical, pathological, and molecular update 5 years after the nomenclature revision


Author(s): Melo M, Ventura M, Cardoso L, Gaspar da Rocha A, Paiva I, Sobrinho-Simões M, Soares P
Affiliated Institution / ERN: São João University Hospital(CHUSJ) ;
Condition / Disease: Thyroid cancer
Publication: European Journal of Endocrinology v188.2 pR15-R22 Year: 2023 ORPHAcode / other: ORPHA146
DOI: 10.1093/ejendo/lvad004 Keywords: NIFTP,NIFTP molecular,low-risk thyroid neoplasm,non-invasive follicular thyroid neoplasm with papillary-like nuclear feature,thyroid neoplasm,thyroid tumour
MTG8

Adrenal crisis in infants and young children with adrenal insufficiency: Management and prevention


Author(s): Bizzarri C, Capalbo D, Wasniewska MG, Baronio F, Grandone A, Cappa M
Affiliated Institution / ERN: AOU University of Campania "Luigi Vanvitelli", Naples ;
Condition / Disease: Adrenal insufficiency
Publication: Frontiers in Endocrinology v14 Year: 2023 ORPHAcode / other: ORPHA101958
DOI: 10.3389/fendo.2023.1133376 Keywords: adrenal crisis,adrenal insufficiency,child,cortisol,hydrocortisone
MTG1

Triac Treatment Prevents Neurodevelopmental and Locomotor Impairments in Thyroid Hormone Transporter Mct8/Oatp1c1 Deficient Mice


Author(s): Chen J, Salveridou E, Liebmann L, Sundaram SM, Doycheva D, Markova B, Hübner CA, Boelen A, Visser WE, Heuer H, Mayerl S
Affiliated Institution / ERN: University Hospital Essen ;
Condition / Disease: Allan-Herndon-Dudley syndrome, thyroid hormone analog; thyroid hormone transport
Publication: International Journal of Molecular Sciences v24.4 p3452 Year: 2023 ORPHAcode / other: ORPHA59; ORPHA596426; ORPHA101955
DOI: 10.3390/ijms24043452 Keywords: Allan-Herndon-Dudley syndrome,Ditpa,SLC16A2,SLCO1C1,Triac,thyroid hormone analog,thyroid hormone transport
MTG8

Novel AIP mutation in exon 6 causing acromegaly in a German family


Author(s): Detomas M, Altieri B, Flitsch J, Saeger W, Korbonits M, Deutschbein T
Affiliated Institution / ERN: University Hospital Würzburg ;
Condition / Disease: Acromegaly
Publication: Journal of Endocrinological Investigation v46.8 p1705-1709 Year: 2023 ORPHAcode / other: ORPHA963
DOI: 10.1007/s40618-023-02031-5 Keywords: AIP,Acromegaly,Colorectal cancer,Familial,GH,Gene,Growth hormone,Mutation,Pituitary adenoma,Twins
MTG6

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia


Author(s): van’t Westeinde A, Karlsson L, Messina V, Wallensteen L, Brösamle M, Dal Maso G, Lazzerini A, Kristensen J, Kwast D, Tschaidse L, Auer MK, Nowotny HF, Persani L, Reisch N, Lajic S
Affiliated Institution / ERN: IRCCS Auxologico Italian Institute - Milan ; Klinikum der Universität München ;
Condition / Disease: Congenital Adrenal Hyperplasia
Publication: Endocrine Connections Volume 12: Issue 4 Year: 2023 ORPHAcode / other: ORPHA418
DOI: 10.1530/ec-22-0400 Keywords: CAH,brain development,dexamethasone,first trimester,prenatal treatment,treatment safety
MTG1

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia


Author(s): van’t Westeinde A, Karlsson L, Messina V, Wallensteen L, Brösamle M, Dal Maso G, Lazzerini A, Kristensen J, Kwast D, Tschaidse L, Auer MK, Nowotny HF, Persani L, Reisch N, Lajic S
Affiliated Institution / ERN: Karolinska University Hospital ; Charité Universitätsmedizin Berlin ; Aarhus University Hospital ; Antonio Cardarelli Hospital - Naples ;
Condition / Disease: Congenital Adrenal Hyperplasia
Publication: Endocrine Connections v12.4 Year: 2023 ORPHAcode / other: ORPHA418
DOI: 10.1530/EC-22-0400 Keywords: CAH,brain development,dexamethasone,first trimester,prenatal treatment,treatment safety
MTG7

Growth patterns and outcomes of growth hormone therapy in patients with acrodysostosis


Author(s): Ertl D, Mantovani G, de Nanclares GP, Elli FM, Pereda A, Pagnano A, Sanchis A, Cueto-Gonzalez AM, Berrade S, León MC, Rothenbuhler A, Audrain C, Berkenou J, Knight N, Dolman K, Gleiss A, Argente J, Linglart A
Affiliated Institution / ERN: Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan ;
Condition / Disease: Acrodysostosis Type 2 (iPPSD5)
Publication: Journal of Endocrinological Investigation v46.8 p1673-1684 Year: 2023 ORPHAcode / other: ORPHA950
DOI: 10.1007/s40618-023-02026-2 Keywords: Acrodysostosis,Auxology,Inactivating PTH/PTHrP signaling disorders,Pediatric,Recombinant human growth hormone,SGA,Short stature
MTG2

Prader–Willi syndrome: Symptoms and topiramate response in light of genetics


Author(s): Louveau C, Turtulici M, Consoli A, Poitou C, Coupaye M, Krebs M, Chaumette B, Iftimovici A
Affiliated Institution / ERN: Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière ;
Condition / Disease: Prader Willi syndrome
Publication: Frontiers in Neuroscience v17 Year: 2023 ORPHAcode / other: ORPHA739
DOI: 10.3389/fnins.2023.1126970 Keywords: Prader–Willi,deletion,disomy,genetics,personalized medicine,topiramate,treatment
MTG5

Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocol


Author(s): Clement SC, Visser WE, Lebbink CA, Albano D, Claahsen-van der Grinten HL, Czarniecka A, Dias RP, Dierselhuis MP, Dzivite-Krisane I, Elisei R, Garcia-Burillo A, Izatt L, Kanaka-Gantenbein C, Krude H, Lamartina L, Lorenz K, Luster M, Navardauskaitė R, Negre Busó M, Newbold K, Peeters RP, Pellegriti G, Piccardo A, Priego AL, Redlich A, de Sanctis L, Sobrinho-Simões M, van Trotsenburg ASP, Verburg FA, Vriens M, Links TP, Ahmed SF, van Santen HM
Affiliated Institution / ERN: Unidade Local de Saúde de Santa Maria(ULS de Santa Maria) ; University Medical Center Groningen ; University Medical Center Utrecht ; Amsterdam UMC ; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan ; Aghia Sophia Children’s Hospital ; Charité Universitätsmedizin Berlin ; AO City of Health and Science - Turin ;
Condition / Disease: Pediatric Thyroid cancer
Publication: Endocrine Connections Volume 12: Issue 3 Year: 2023 ORPHAcode / other: ORPHA146
DOI: 10.1530/ec-22-0306 Keywords: DTC,childhood,registry,thyroid carcinoma
MTG8

Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review


Author(s): Van Cauwenberghe J, De Block C, Vanderschueren D, Antonio L
Affiliated Institution / ERN: UZ Antwerpen ;
Condition / Disease: testosterone and diabetes
Publication: Andrology v11.2 p225-233 Year: 2023 ORPHAcode / other:
DOI: 10.1111/andr.13318 Keywords: GLP1 receptor analogues,antidiabetic agents,antihyperglycemic agents,functional hypogonadism,hypogonadism,obesity
MTG3

Prospective evaluation of multidimensional health‐related quality of life after endoscopic endonasal surgery for pituitary adenomas using the endoscopic endonasal sinus and skull base surgery questionnaire


Author(s): Joustra GE, ten Dam E, Vermeulen KM, Korsten‐Meijer AGW, Appelman APA, Feijen RA
Affiliated Institution / ERN: University Medical Center Groningen ;
Condition / Disease: Acromegaly
Publication: Laryngoscope Investigative Otolaryngology v8.1 p7-15 Year: 2023 ORPHAcode / other: ORPHA963
DOI: 10.1002/lio2.1004 Keywords: anterior skull base,endoscopic endonasal sinus and Skull Base surgery questionnaire (EES‐Q),endoscopic skull base surgery,patient reported outcome measure,quality of life
MTG6

Pituitary enlargement in patients with cerebrospinal fluid drainage due to ventricular shunt insertion: know the condition and do not mistake for adenoma


Author(s): Grzywotz A, Li Y, Unger N, Kiewert C, Chmielewski WX, Sure U, Uerschels A, Wrede K, Kreitschmann-Andermahr I
Affiliated Institution / ERN: University Hospital Essen ;
Condition / Disease: Pituitary adenoma
Publication: Pituitary v26.1 p164-170 Year: 2023 ORPHAcode / other: ORPHA99408
DOI: 10.1007/s11102-022-01296-y Keywords: CSF pressure,ICP,Pituitary enlargement,Pituitary hyperplasia,Shunt insertion
MTG6

Teplizumab approval for type 1 diabetes in the USA


Author(s): Beran D, Abidha C, Adler A, de Beaufort C, Lepeska M, Levitt N, Pfiester E, Zafra-Tanaka JH, Gale EA
Affiliated Institution / ERN: Centre Hospitalier de Luxembourg ;
Condition / Disease: diabetes type 1; Teplizumab;
Publication: The Lancet Diabetes & Endocrinology v11.2 p78-80 Year: 2023 ORPHAcode / other:
DOI: 10.1016/s2213-8587(22)00384-9 Keywords:
MTG3

Fluctuations in Thyroid Hormone Levels During Initial Treatment for Differentiated Thyroid Carcinoma are Associated with Changes in Hemostasis: A Prospective Cohort Study


Author(s): Links MH, Lefrandt JD, Lisman T, van der Boom T, Lukens MV, Meijer K, Links TP, Zandee WT
Affiliated Institution / ERN: University Medical Center Groningen ;
Condition / Disease: Thyroid cancer
Publication: Thyroid v33.2 p203-213 Year: 2023 ORPHAcode / other: ORPHA146
DOI: 10.1089/thy.2022.0299 Keywords: TH withdrawal,THST,cardiovascular risk,differentiated thyroid carcinoma,hemostasis,thrombosis
MTG8

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial


Author(s): Battelino T, Danne T, Edelman SV, Choudhary P, Renard E, Westerbacka J, Mukherjee B, Pilorget V, Coudert M, Bergenstal RM
Affiliated Institution / ERN: University Medical Centre Ljubljana ;
Condition / Disease: Diabetes mellitus
Publication: Diabetes, Obesity and Metabolism v25.2 p545-555 Year: 2023 ORPHAcode / other:
DOI: 10.1111/dom.14898 Keywords: basal insulin,continuous glucose monitoring,glycaemic control,insulin analogues,randomized trial,type 1 diabetes
MTG3

In Search of the Hyperglycemic Threshold Required to Induce Growth Hormone (GH) Suppression


Author(s): Bugalho MJ, Lopes-Pinto M, Lemos C, Nobre E
Affiliated Institution / ERN: Unidade Local de Saúde de Santa Maria(ULS de Santa Maria) ;
Condition / Disease: Acromegaly
Publication: Cureus doi:10.7759/cureus.34463 Year: 2023 ORPHAcode / other: ORPHA963
DOI: 10.7759/cureus.34463 Keywords: acromegaly,growth hormone,hyperglycemia,oral glucose tolerance test,suppression test
MTG6

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria


Author(s): Kamusheva M, Vandeva S, Mitov K, Parvanova A, Pesheva M, Ganov N, Rusenova Y, Marinov L, Getova V, Elenkova A, Petrova G
Affiliated Institution / ERN: USHATE “ACAD IVAN Penchev” ;
Condition / Disease: Acromegaly
Publication: Pharmaceutics v15.2 p438 Year: 2023 ORPHAcode / other: ORPHA963
DOI: 10.3390/pharmaceutics15020438 Keywords: Bulgaria,acromegaly,adherence
MTG6

Multicentric Italian case–control study on 25OH vitamin D levels in children and adolescents with Prader-Willi syndrome


Author(s): Panfili FM, Convertino A, Grugni G, Mazzitelli L, Bocchini S, Crinò A, Campana G, Cappa M, Delvecchio M, Faienza MF, Licenziati MR, Mariani M, Osimani S, Pajno R, Patti G, Rutigliano I, Sacco M, Scarano E, Fintini D
Affiliated Institution / ERN: AOU-Bologna ;
Condition / Disease: Prader-Willi syndrome
Publication: Journal of Endocrinological Investigation v46.7 p1397-1406 Year: 2023 ORPHAcode / other: ORPHA739
DOI: 10.1007/s40618-022-01990-5 Keywords: 25OHD,GH therapy,Insulin resistance,Obesity,Prader-Willi syndrome,Vitamin D
MTG5

Mapping of the current transition of care practice for patients with pituitary disease at Endo-ERN reference centers


Author(s): Shishkov SR, Tuccillo L, Iotova VM, Pivonello R, Pelsma IC, Pereira AM, Biermasz NR, and the Endo-ERN Reference Centers of the Main Thematic Group: Hypothalmic and Pituitary Conditions, Endo-ERN Pituitary Transition of Care Study Group
Affiliated Institution / ERN: UMHAT “Sveta Marina” (Varna) ; Leiden University Medical Center ;
Condition / Disease: pituitary conditions; transition survey;
Publication: Endocrine Connections Volume 12: Issue 2 Year: 2023 ORPHAcode / other: ORPHA99408; ORPHA95502
DOI: 10.1530/ec-22-0308 Keywords: Endo-ERN,pituitary disease,quality of care,survey,transition of care
MTG6

Methylation status of hypothalamic Mkrn3 promoter across puberty


Author(s): Fanis P, Morrou M, Tomazou M, Michailidou K, Spyrou GM, Toumba M, Skordis N, Neocleous V, Phylactou LA
Affiliated Institution / ERN: Cyprus Institute of Neurology and Genetics ;
Condition / Disease: Central Precocious Puberty
Publication: Frontiers in Endocrinology v13 Year: 2023 ORPHAcode / other: ORPHA650182
DOI: 10.3389/fendo.2022.1075341 Keywords: CpG island,DNA methylation,MKRN3,promoter,puberty timing
MTG7

Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome


Author(s): Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, Høberg-Vetti H, Tveit Haavind M, Innella G, Turchetti D, Aretz S, Spier I, Tischkowitz M, Jahn A, Links TP, Olderode-Berends MJW, Blatnik A, Leter EM, Evans DG, Woodward ER, Steinke-Lange V, Anastasiadou VC, Colas C, Villy M, Benusiglio PR, Gerasimenko A, Barili V, Branchaud M, Houdayer C, Tesi B, Yazicioglu MO, van der Post RS, Schuurs-Hoeijmakers JHM, van Hest LP, Adank MA, Duijkers F, Nielsen M, Verbeek KCJ, van Ierland Y, Giltay JC, Vos JR, Vos JR
Affiliated Institution / ERN: University Medical Center Groningen ;
Condition / Disease: Familial Genetic Tumour Syndromes
Publication: JNCI: Journal of the National Cancer Institute v115.1 p93-103 Year: 2023 ORPHAcode / other: ORPHA306498
DOI: 10.1093/jnci/djac188 Keywords:
MTG4

Pre-Surgery Patient Health Contributes to Aggravated Sino-Nasal Outcome and Quality of Life after Pituitary Adenomectomy


Author(s): Chmielewski WX, Walbrodt S, Rauschenbach L, Chihi M, Gembruch O, Darkwah Oppong M, Schroer S, Wrede KH, Dammann P, Jabbarli R, Kreitschmann-Andermahr I, Sato T, Unger N, Mattheis S, Sure U, Ahmadipour Y
Affiliated Institution / ERN: University Hospital Essen ;
Condition / Disease: pituitary adenoma
Publication: Medicina v59.1 p127 Year: 2023 ORPHAcode / other: ORPHA99408
DOI: 10.3390/medicina59010127 Keywords: adenomectomy,health-related quality of life,pituitary adenoma,pre-surgery patient health,sino-nasal health
MTG6

Pediatric growth hormone and prolactin-secreting tumor associated with an AIP mutation and a MEN1 variant of uncertain significance


Author(s): Alexandre MI, Faria CC, Gomes A, Bugalho MJ
Affiliated Institution / ERN: Unidade Local de Saúde de Santa Maria(ULS de Santa Maria) ;
Condition / Disease: Pediatric growth hormone and prolactin secreting tumour
Publication: Journal of Pediatric Endocrinology and Metabolism v0.0 Year: 2023 ORPHAcode / other: ORPHA2965
DOI: 10.1515/jpem-2022-0488 Keywords: genetic testing,gigantism,growth hormone
MTG6

The transition from pediatric to adult care in individuals with Prader-Willi syndrome


Author(s): Poitou C, Holland A, Höybye C, de Graaff LCG, Bottius S, Otterlei B, Tauber M
Affiliated Institution / ERN: Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière ;
Condition / Disease: Prader Willi syndrome
Publication: Endocrine Connections v12.1 Year: 2023 ORPHAcode / other: ORPHA739
DOI: 10.1530/ec-22-0373 Keywords: Prader-Willi syndrome,transition
MTG5

Availability and access to pediatric diabetes care: a global descriptive study


Author(s): Pulungan AB, de Beaufort C, Ratnasari AF, Puteri HA, Lewis-Watts L, Bhutta ZA
Affiliated Institution / ERN: Centre Hospitalier de Luxembourg ;
Condition / Disease: pediatric diabetes care
Publication: Clinical Pediatric Endocrinology v32.3 p137-146 Year: 2023 ORPHAcode / other: ORPHA101952
DOI: 10.1297/cpe.2023-0017 Keywords: access,availability,children,diabetes,type 1 diabetes mellitus (T1DM)
MTG3
Page 12 of 30« First«...1011121314...2030...»Last »

Endo-ERN Newsletter

Subscribe to our newsletter to receive updates on all network activities and new resources. As soon as you subscribe you will receive an email asking you to confirm your registration.

SIGN UP NOW

News

  • All news
  • Newsletter signup

Events

  • Upcoming events
  • Webinars

Information

  • About Us
  • Contact
  • FAQs

Social Links

Linkedin Facebook Youtube

Contact

Endo-ERN
Coordinating Center
Meibergdreef 9
1105 AZ AMSTERDAM
The Netherlands

info@endo-ern.eu
Funded by the European Union
©2025. All Rights Reserved. Endo-ERN

Privacy Policy – GDPR

Website design by Elan Creative

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Information video for patients and healthcare professionals

Type and Press “enter” to Search

Search
Privacy Overview
Endo-ERN

Endo-ERN Privacy Policy

Endo-ERN is committed to user’s privacy and does not track personal data when visiting our website. We act in accordance with Regulation 2016/679 of the European Parliament and of the Council.

‘Personal data’ means any information relating to an identified or identifiable natural person. An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as:

  • a name
  • an identification number
  • location data
  • an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person

Cookies

Endo-ERN only tracks anonymised data for statistical purposes. We do this via analytical cookies, placed through an anonymous IP Google analytics tag. The purpose of these cookies are to track the efficiency and success of the website.

These cookies do not store any personal data that can be linked to a natural person, but may save data such as inter alia, data about the website from which a person has come (the so-called referrer), which sub-pages were visited, or how often and for what duration a sub-page was viewed. The data collected through this is general data only, and cannot be traced back to one person.

It is possible to prevent the setting of cookies, by means of a setting of the Internet browser used. On top of that, already set cookies may be deleted at any time via an Internet browser or other software programs. This is possible in all popular Internet browsers.

Google Analytics does not share any data with third parties.

The principles of data protection do not apply to anonymous information and because these cookies minimally impact the privacy of the user, it is not necessary to ask for permission to use these cookies.

Newsletter

You may always unsubscribe from our newsletter at any time through the unsubscribe button located in our newsletter. Endo-ERN is both the controller and responsible for processing of any data regarding the newsletter. Endo-ERN does not make use of a third party for the Newsletter service.

E-services

Endo-ERN has a contact form, which activates your email software and allows you to send a comment or question to a general email address. When you send such a message, your personal data is collected only to the extent necessary to reply. If the team responsible for the mailbox is unable to answer your question, or your questions has regards to another party, it might forward your email to another service.

If you have any questions about the processing of your email and related personal data, do not hesitate to include them in your message.

The collected personal data and all information related to the above mentioned consultation is stored on the email server of the Endo-ERN Coordinating office and potentially those who have been concerned in the correspondence in order to respond to your comment.

Newsletter Tracking

The Endo-ERN newsletter makes use of tracking in order to be able to conduct a statistical analysis of the success or failure of online marketing campaigns. Endo-ERN may see if an email containing a newsletter was opened by a user, when it was opened, and which links were opened. 
The data collected through this tracking is generated and stored by Endo-ERN and is not shared with third parties, but may be used to adapt future content of newsletters in order to better meet the interests of our subscribers.

Contact details

For any questions regarding our privacy policy, please contact the Endo-ERN coordinating office.

You have the right to be forgotten and removed completely from the Endo-ERN contact database. To request this, please contact the Endo-ERN coordinating office.

Endo-ERN Coordinating Center, Meibergdreef 9, 1105 AZ  AMSTERDAM. The Netherlands

 info@endo-ern.eu
Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Powered by  GDPR Cookie Compliance